Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
2 participants in 3 patient groups
Loading...
Central trial contact
Alexion Pharmaceuticals, Inc.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal